BGB-24714 / BeOne Medicines - LARVOL DELTA

Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, in a first-in-human study in solid tumors (AACR 2026) - P1 | "BGB-24714 demonstrated potent, sustained target engagement, apoptosis induction, and immune-inflammatory modulation consistent with its SMAC mimetic mechanism of action. These translational PD results support the biological activity of BGB-24714 in patients with solid tumors."

First-in-human • P1 data • PK/PD data • Breast Cancer • Oncology • Solid Tumor • KRT18

A phase 1 study of BGB-24714, a second mitochondrial-derived activator of caspases (SMAC) mimetic, as monotherapy or in combination with chemotherapy or concurrent chemoradiotherapy in solid tumors (AACR 2026) - P1 | "Ph1b enrolled pts with second-line or later metastatic NSCLC and platinum-resistant ovarian cancer (PROC) to receive BGB-24714 + docetaxel or paclitaxel, respectively. BGB-24714 demonstrated antitumor activity with a manageable safety profile in pts with advanced or metastatic solid tumors."

Combination therapy • First-in-human • Monotherapy • P1 data • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma

BGB-24714-101: A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=157 | Terminated | Sponsor: BeiGene | Trial completion date: Nov 2026 ➔ Jul 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Oct 2025 ➔ Jul 2025; The research was terminated voluntarily due to changes in the company's business strategy regarding the development of BGB-24714, rather than any safety issues.

Monotherapy • Trial completion date • Trial primary completion date • Trial termination • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BGB-24714-101: A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=157 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=229 | Recruiting | Sponsor: BeiGene | N=168 ➔ 229

Combination therapy • Enrollment change • Monotherapy • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=168 | Recruiting | Sponsor: BeiGene | Trial completion date: Jul 2027 ➔ Nov 2026 | Trial primary completion date: Jan 2027 ➔ Dec 2025

Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=168 | Recruiting | Sponsor: BeiGene | N=284 ➔ 168 | Trial completion date: Jan 2025 ➔ Jul 2027 | Trial primary completion date: Jul 2024 ➔ Jan 2027

Combination therapy • Enrollment change • Monotherapy • Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel (AACR 2023) - P1 | "BGB-24714 effectively inhibited cIAP1 by inducing its degradation in MDA-MB-231 cells, with an EC50 of 2.5 nM. BGB-24714 also potently antagonized the inhibitory interaction of XIAP with caspase-9 and induced caspase-9 autoactivation in MDA-MB-231 cells, with an EC50 of 23 nM. In a total of 25 breast cancer cell lines treated with TNFα, BGB-24714 potently inhibited the in vitro proliferation of 5 breast cancer cells with EC50 < 100 nM."

Combination therapy • Monotherapy • Preclinical • Breast Cancer • Oncology • Solid Tumor • CASP9 • TNFA • XIAP

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=244 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Monotherapy • Oncology • Solid Tumor

Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=244 | Not yet recruiting | Sponsor: BeiGene

Combination therapy • Monotherapy • New P1 trial • Oncology • Solid Tumor